Randomized controlled trial of interferon-beta-1a in secondary progressive MS

Objective: To examine MRI changes resulting from treatment of secondary progressive MS (SPMS) with two doses of interferon-beta-1a (Rebif). Background: Interferon-beta (IFN-β) reduces relapses and delays progression in relapsing-remitting MS, but there are conflicting results on its clinical benefit in SPMS. Methods: In a double-blind, randomized, multicenter, placebo-controlled study (SPECTRIMS), 618 patients received IFN-β-1a 22 μg, 44 μg, or placebo subcutaneously three times weekly for 3 years. T2 activity and burden of disease (BOD) were measured in 617 patients by using semiannual proton density/T2-weighted (PD/T2) MRI scans. A cohort of 283 patients also had 11 monthly PD/T2 and T1-weighted gadolinium-enhanced (T1-Gd) scans at study start. Results: Treatment reduced median numbers of active lesions per patient per scan (semiannual T2 activity: 0.17, 0.20 and 0.67 for the high dose, low dose, and placebo, p < 0.0001; monthly combined unique activity [T1+T2]: 0.11, 0.22, and 1.00, p < 0.0001) and accumulation of BOD (percent change from baseline to month 36: −1.3, −0.5, and 10.0 for the high dose, low dose, and placebo, respectively; p = 0.0001). MRI benefit was most evident in the subgroup of patients who reported relapses in the 2 years before the study. Neutralizing antibody development was associated with reduction in treatment effect: antibody-positive patients did not show significant differences from placebo at either dose. Conclusions: Interferon-β-1a used in SPMS showed significant effects on all MRI measures, particularly in patients with relapses in the 2 years before the study.

[1]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[2]  R. Kikinis,et al.  Longitudinal MRI in multiple sclerosis , 1994, Neurology.

[3]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[4]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[5]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[6]  P. O'Brien.  Procedures for comparing samples with multiple endpoints. , 1984, Biometrics.

[7]  D. Li,et al.  Lesion load reproducibility and statistical sensitivity of clinical trials in multiple sclerosis. , 1999, Neurology.

[8]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[9]  P. Matthews,et al.  Chemical pathology of acute demyelinating lesions and its correlation with disability , 1995, Annals of neurology.

[10]  Jeanelle Sheeder,et al.  Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis , 1998 .

[11]  Ludwig Kappos,et al.  Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis , 1998, The Lancet.

[12]  N. Simonian,et al.  “Summary measure” statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis , 1998, Journal of neurology, neurosurgery, and psychiatry.

[13]  B D Trapp,et al.  Axonal pathology in multiple sclerosis: relationship to neurologic disability. , 1999, Current opinion in neurology.

[14]  D. Goldberg,et al.  A scaled version of the General Health Questionnaire , 1979, Psychological Medicine.

[15]  Ludwig Kappos,et al.  Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis , 1999, The Lancet.

[16]  S. Reingold,et al.  Defining the clinical course of multiple sclerosis , 1996, Neurology.

[17]  J. Taubenberger,et al.  Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis , 1993, Annals of neurology.

[18]  A. Thompson,et al.  Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[19]  G. Barker,et al.  Effect of interferon‐β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double‐blind, placebo‐controlled trial , 1999 .

[20]  D. Paty,et al.  Magnetic resonance imaging results of the PRISMS trial: A randomized, double‐blind, placebo‐controlled study of interferon‐β1a in relapsing‐remitting multiple sclerosis , 1999 .

[21]  P M Matthews,et al.  Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis , 1991, Neurology.

[22]  W. I. McDonald,et al.  Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis , 1994, Neurology.